Listen to the Bloomberg interview of Dr Jacobs, CEO of SGYP. He said they now have 140 employees, with many in sales. That is a clear message that they shopped the company and found no takers so they are going it alone. That is why, I expect, you're seeing continued pressure on the share price. The had like 7 employees 12 months ago, so they really ramped up. Trouble is they need the reach the GP docs as well as specialist and you can't do that as a micro cap biotech. That is why Ironwood and Sucampo took the big Pharma partnership route. I thought for sure they would be bought out. Full disclosure: I have not owned SGYP for over a year.
News 
Market Data 
Discover 
